Estrella Immunopharma (NASDAQ:ESLA) Downgraded by Wall Street Zen to Sell

Estrella Immunopharma (NASDAQ:ESLA) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

ESLA has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Estrella Immunopharma in a report on Friday, October 31st. D. Boral Capital reissued a “buy” rating and issued a $16.00 price objective on shares of Estrella Immunopharma in a research note on Monday, November 3rd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Estrella Immunopharma has a consensus rating of “Hold” and a consensus price target of $16.00.

Estrella Immunopharma Stock Performance

Shares of NASDAQ ESLA opened at $0.99 on Friday. The firm’s fifty day moving average is $1.68 and its two-hundred day moving average is $1.41. Estrella Immunopharma has a 52-week low of $0.73 and a 52-week high of $3.15. The company has a market cap of $37.54 million, a P/E ratio of -2.92 and a beta of 0.55.

Estrella Immunopharma (NASDAQ:ESLA) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.06.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.